Northwick Park hospital clinical trial incident in 2006

Six healthy young men were treated for organ failure after experiencing a serious reaction within hours of taking the CD28-SuperMAB in a clinical trial despite being administered at a supposed sub-clinical dose of 0.1 mg per kg which is 500 times lower than the dose found safe in animals.


CD28-SuperMAB is an immunomodulatory drug intended for treatment of B cell chronic lymphocytic leukaemia and rheumatoid arthritis. It is a humanised monocloncal antibody that is a strong agonist for CD28 receptor of the immune T cells.


The MHRA (Medicines and Health products Regulatory Agency) in UK now ensures that committees look at pre-clinical data to decide whether the first dose given to humans is the right dose.

Featured Posts
Posts are coming soon
Stay tuned...
Recent Posts
Archive
Search By Tags
No tags yet.
Follow Us
  • LinkedIn Social Icon
  • Twitter Basic Square